A confirmed MSH2-associated Lynch syndrome diagnosis provided a unifying biological explanation for multiple primary cancers ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Researchers report encouraging long-term results from an experimental treatment approach that rethinks the timing of cancer ...

Getting a cancer diagnosis is devastating. But a new clinical trials resource is making it easier for both patients and ...

Colorectal Cancer Alliance Urges Action for Women’s Health and Clinical Trials Awareness Month Many young people and ...

Most patients with pancreatic cancer report they were never offered the opportunity to participate in clinical trials.A ...

There is some promising news for pancreatic cancer research, as medical data show lasting results from the trial of a vaccine ...

Independent, academic clinical cancer trials are essential to improving patient outcomes, reducing inequalities in care, and ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

START and OneOncology are partnering to launch three new early-phase cancer trial sites in California, Texas, and New Jersey, expanding access to cutting-edge research in community oncology settings.

Martei is a medical oncologist, cancer outcomes researcher, and an assistant professor of medicine at the University of Pennsylvania. At the American Society of Clinical Oncology annual meeting last ...